title: Maintenance of surgically induced remission of Crohn's disease.
abstract: At 1 year after a first resection, up to 80% of patients show an endoscopic recurrence, 10-20% have clinical relapse, and 5% have surgical recurrence. Smoking is one of the most important risk factors for postoperative recurrence. Preoperative disease activity and the severity of endoscopic lesions in the neoterminal ileum within the first postoperative year are predictors of symptomatic recurrence. Mesalazine is generally the first-line treatment used in the postoperative setting but still provokes considerable controversy as to its efficacy, in spite of the results of a meta-analysis. Immunosuppressive treatment (azathioprine, 6-mercaptopurine) is based on scant evidence but is currently used as a second-line treatment in postsurgical patients at high risk for recurrence, with symptoms or with early endoscopic lesions in the neoterminal ileum. Nitroimidazole antibiotics (metronidazole, ornidazole) are also effective in the control of active Crohn's disease in the postoperative setting. Given their known toxicity, they may be used as a third-line treatment as initial short-term prevention therapy rather than in the long term. Conventional corticosteroids, budesonide or probiotics have no proven role in postoperative prophylaxis. Infliximab has not as yet been studied for use in the prevention of relapse after surgery.
authors.affiliation: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. florian.froehlich@bluewin.ch
authors.forename: Florian
authors.initials: F
authors.lastname: Froehlich
authors.forename: Pascal
authors.initials: P
authors.lastname: Juillerat
authors.forename: Valérie
authors.initials: V
authors.lastname: Pittet
authors.forename: Christian
authors.initials: C
authors.lastname: Felley
authors.forename: Christian
authors.initials: C
authors.lastname: Mottet
authors.forename: John-Paul
authors.initials: JP
authors.lastname: Vader
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Gonvers
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy / Q000601:surgery*; D004359:Drug Therapy, Combination; D016099:Endoscopy, Gastrointestinal; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011182:Postoperative Care; D012008:Recurrence; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents